Pharmacological profile of AS-9705, a novel benzotriazolecarboxamide derivative, as a gastroprokinetic agent with potent anti-emetic activity

Arzneimittel-Forschung/Drug Research

Volumn 53, Issue 2, 2003, Pages 98-106

  Yoshikawa, Takashi ^a   Mine, Yukiko ^a   Morikage, Kazuo ^a   Yoshida, Naoyuki ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

(R) N (1 Ethyl 1H hexahydroazepin 3 yl) 6 methoxy 1H benzotriazole 5 carboxamide fumarate monohydrate; Anti emetic; AS 9705, anti emetic effect, dog, ferret, pharmacological profile; CAS 219622 61 4; Gastroprokinetic agent

Indexed keywords

1 METHYL 3 INDOLECARBOXYLIC ACID [1 [2 (METHYLSULFONYLAMINO)ETHYL] 4 PIPERIDINYLMETHYL] ESTER; 2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 3 (5 METHYL 1H IMIDAZOL 4 YL) 1 (1 METHYL 1H INDOL 3 YL) 1 PROPANONE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMIDE; APOMORPHINE; AS 9705; BUTACLAMOL; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CISAPRIDE; CISPLATIN; CLONIDINE; DOMPERIDONE; DOPAMINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; KETANSERIN; METHYSERGIDE; METOCLOPRAMIDE; MORPHINE; N (1 ETHYL 1H HEXAHYDROAZEPIN 3 YL) 6 METHOXY 1H BENZOTRIAZOLE 5 CARBOXAMIDE FUMARATE MONOHYDRATE; PROKINETIC AGENT; RADIOLIGAND; SEROTONIN; SPIPERONE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTIEMETIC ACTIVITY; ARTICLE; CATALEPSY; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG STRUCTURE; EXPLORATORY BEHAVIOR; FERRET; GASTROINTESTINAL MOTILITY; GNAWING; IC 50; LIGAND BINDING; MALE; NONHUMAN; RAT; STOMACH EMPTYING; STOMACH MOTILITY; VOMITING;

EID: 0037283053     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1297079     Document Type: Article

References (26)

1. Prakash, A., Wagstaff, A. J., Domperidone. A review of its use in diabetic gastropathy. Drugs 56, 429 (1998)
2. Barone, J. A., Domperidone: a peripherally acting dopamine2-receptor antagonist. Ann. Pharmacother. 33, 429 (1999)
3. Champion, M. C., Domperidone. Gen. Pharmacol. 19, 499 (1988)
4. Takahashi, T., Kurosawa, S., Wiley, J. W. et al., Mechanism for the gastrokinetic action of domperidone. In vitro studies in guinea pigs. Gastroenterology 101, 703 (1991)
5. Tazawa, S., Masuda, N., Koizumi, T. et al., KDR-5169, a new gastrointestinal prokinetic agent, enhances gastric contractile and emptying activities in dogs and rats. Eur. J. Pharmacol. 434, 169 (2002)
6. Taniyama, K., Makimoto, N., Furuichi, A. et al., Functions of peripheral 5-hydroxytryptamine receptors, especially 5-hydroxytryptamine4 receptor, in gastrointestinal motility. J. Gastroenterol. 35, 575 (2000)
7. Yoshida, N., Ito, T., Karasawa, T. et al., AS-4370, a new gastrokinetic agent, enhances upper gastrointestinal motor activity in conscious dogs. J. Pharmacol. Exp. Ther. 257, 781 (1991)
8. Mine, Y., Yoshikawa, T., Oku, S. et al., Comparison of effect of mosapride citrate and existing 5-HT4 receptor agonists on gastrointestinal motility in vivo and in vitro. J. Pharmacol. Exp. Ther. 283, 1000 (1997)
9. Hasler, W. L., Serotonin receptor physiology: relation to emesis. Dig. Dis. Sci. 44, 108S (1999)
10. Sunahara, R. K., Guan, H. C., O'Dowd, B. F. et al., Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature 350, 614 (1991)
11. Van Tol, H. H., Bunzow, J. R., Guan, H. C. et al., Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350, 610 (1991)
12. Levesque, D., Diaz, J., Pilon, C. et al., Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc. Natl. Acad. Sci. USA 89, 8155 (1992)
13. Peroutka, S. J., Pharmacological differentiation and characterization of 5-HT1A, 5-HT1B, and 5-HT1C binding sites in rat frontal cortex. J. Neurochem. 47, 529 (1986)
14. Millan, M. J., Canton, H., Gobert, A. et al., Novel benzodioxopiperazines acting as antagonists at postsynaptic 5-HT1A receptors and as agonists at 5-HT1A autoreceptors: a comparative pharmacological characterization with proposed 5-HT1A antagonists. J. Pharmacol. Exp. Ther. 268, 337 (1994)
15. 3H]Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role. Mol. Pharmacol. 21, 301 (1982)
16. Kilpatrick, G. J., Jones, B. J., Tyers, M. B., Binding of the 5-HT3 ligand, [3H]GR65630, to rat area postrema, vagus nerve and the brains of several species. Eur. J. Pharmacol. 159, 157 (1989)
17. Grossman, C. J., Kilpatrick, G. J., Bunce, K. T., Development of a radioligand binding assay for 5-HT4 receptors in guinea-pig and rat brain. Br. J. Pharmacol. 109, 618 (1993)
18. Scarpignato, C., Capovilla, T., Bertaccini, G., Action of caerulein on gastric emptying of the conscious rat. Arch. Int. Pharmacodyn. Ther. 246, 286 (1980)
19. Itoh, Z., Honda, R., Takeuchi, S. et al., An extraluminal force transducer for recording contractile activity of the gastrointestinal smooth muscle in the conscious dogs: its construction and implantation. Gastroenterol. Jpn. 12, 275 (1977)
20. King, G. L., Animal models in the study of vomiting. Can. J. Physiol. Pharmacol. 68, 260 (1990)
21. Yoshida, N., Yoshikawa, T., Hosoki, K., A dopamine D3 receptor agonist, 7-OH-DPAT, causes vomiting in the dog. Life Sci. 57, PL347 (1995)
22. Yoshikawa, T., Yoshida, N., Hosoki, K., Involvement of dopamine D3 receptors in the area postrema in R(+)-7-OH-DPAT-induced emesis in the ferret. Eur. J. Pharmacol. 22, 143 (1996)
23. Lang, I. M., Marvig, J., Functional localization of specific receptors mediating gastrointestinal motor correlates of vomiting. Am. J. Physiol. 256, G92 (1989)
24. Itoh, Z., Motilin, p. 133-153. Academic Press, New York (1990)
25. Kaput, S., Zipursky, R., Jones, C. et al., Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiat. 157, 514 (2000)
26. Ponti, F. D., Poluzzi, E., Cavalli, A. et al., Safety of Non-Antiarrhythmic Drugs that Prolong the QT Interval or Induce Torsade de Pointes: An Overview. Drug Safety 25, 263 (2002)